OLFML3 and neoplasm: Bevacizumab treatment of DLD1-xenograft-bearing mice reduced the expression of mouse Olfml3 (host-derived) and human OLFML3 (tumor-derived, although not significantly) mRNA in tumor samples (Figure 2F).